Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;105(3):228-34.
doi: 10.5935/abc.20150075. Epub 2015 Jul 3.

Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity?

[Article in English, Portuguese]
Sarita Lígia Pessoa de Melo Machado Guimarães  1 , Simone Cristina Soares Brandão  1 , Luciana Raposo Andrade  2 , Rafael José Coelho Maia  1 , Brivaldo Markman Filho  1
Affiliations

Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity?

[Article in English, Portuguese]
Sarita Lígia Pessoa de Melo Machado Guimarães et al. Arq Bras Cardiol. 2015 Sep.

Abstract

Background: Chemotherapy with anthracyclines and trastuzumab can cause cardiotoxicity. Alteration of cardiac adrenergic function assessed by metaiodobenzylguanidine labeled with iodine-123 (123I-mIBG) seems to precede the drop in left ventricular ejection fraction.

Objective: To evaluate and to compare the presence of cardiovascular abnormalities among patients with breast cancer undergoing chemotherapy with anthracyclines and trastuzumab, and only with anthracycline.

Methods: Patients with breast cancer were analyzed clinical, laboratory, electrocardiographic and echocardiographic and cardiac sympathetic activity. In scintigraphic images, the ratio of 123I-mIBG uptake between the heart and mediastinum, and the washout rate were calculated. The variables were compared between patients who received anthracyclines and trastuzumab (Group 1) and only anthracyclines (Group 2).

Results: Twenty patients, with mean age 57 ± 14 years, were studied. The mean left ventricular ejection fraction by echocardiography was 67.8 ± 4.0%. Mean washout rate was 28.39 ± 9.23% and the ratio of 123I-mIBG uptake between the heart and mediastinum was 2.07 ± 0.28. Of the patients, 82% showed an increased in washout rate, and the ratio of 123I-mIBG uptake between the heart and mediastinum decreased in 25%. Concerning the groups, the mean washout rate of Group 1 was 32.68 ± 9.30% and of Group 2 was 24.56 ± 7.72% (p = 0,06). The ratio of 123I-mIBG uptake between the heart and mediastinum was normal in all patients in Group 2, however, the Group 1, showed 50% the ratio of 123I-mIBG uptake between the heart and mediastinum ≤ 1.8 (p = 0.02).

Conclusion: In women with breast cancer undergoing chemotherapy, assessment of cardiac sympathetic activity with 123I-mIBG appears to be an early marker of cardiotoxicity. The combination of chemotherapy showed higher risk of cardiac adrenergic hyperactivity.

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Cardiac scintigraphy with 123I-mIBG of a study patient at the anterior chest view 10 minutes (early) and 4 hours (late) after injection of 123I-mIBG. Upper panel: black-and-white images; lower panel: color images. LV: left ventricle.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kalil Filho R, Hajjar LA, Bacal F, Hoff PM, Diz Mdel P, Galas FR, et al. 1ª Diretriz brasileira de cardio-oncologiada Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2011;96(2) Supl.1:1–52. - PubMed
    1. American Cancer Society Patient navigator program helps guide, support, and inform thousands of cancer patients through every step of their journey. [2011 Nov 25]. Available from: http://www.cancer.org/treatment/
    1. Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012;13(3):e95–e102. - PubMed
    1. Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol. 2003;30(5) Suppl 16:49–53. - PubMed
    1. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation. 2000;102(3):272–274. - PubMed

MeSH terms